OCULAR THERAPEUTIX, INC Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
OCULAR THERAPEUTIX, INC (OCUL) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 1.36 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-06-30 was 1.36K shares, a 94.59% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-03-31 was 52.47K shares.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-09-30 was 88.88K shares.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2025-06-30 was 25.09K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month |
|---|---|---|---|
| 2026-06-30 | 1.36K shares 10-Q · filed 2026-08-03 | 188.32K shares 10-Q · filed 2026-08-03 | |
| 2026-03-31 | 52.47K shares 10-Q · filed 2026-05-05 | ||
| 2025-09-30 | 88.88K shares 10-Q · filed 2025-11-04 | 113.97K shares derived: sum of 2 quarters · filed 2025-11-04 | 216.75K shares 10-Q · filed 2025-11-04 |
| 2025-06-30 | 25.09K shares 10-Q · filed 2025-08-05 | 127.86K shares 10-Q · filed 2025-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |